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BaCKgRoUND aND aIMS: Sustained virologic response 
(SVR) to interferon (IFN)-free therapies ameliorates portal 
hypertension (PH); however, it remains unclear whether a 
decrease in hepatic venous pressure gradient (HVPG) after 
cure of hepatitis C translates into a clinical benefit. We as-
sessed the impact of pretreatment HVPG, changes in HVPG, 
and posttreatment HVPG on the development of hepatic 
decompensation in patients with PH who achieved SVR to 
IFN-free therapy. Moreover, we evaluated transient elastogra-
phy (TE) and von Willebrand factor to platelet count ratio 
(VITRO) as noninvasive methods for monitoring the evolu-
tion of PH.
appRoaCH aND ReSUltS: The study comprised 90 
patients with HVPG  ≥  6  mm  Hg who underwent paired 
HVPG, TE, and VITRO assessments before (baseline [BL]) 
and after (follow-up [FU]) IFN-free therapy. FU HVPG 
but not BL HVPG predicted hepatic decompensation (per 
mm  Hg, hazard ratio, 1.18; 95% confidence interval, 1.08-
1.28; P  <  0.001). Patients with BL HVPG  ≤  9  mm  Hg 
or patients who resolved clinically significant PH (CSPH) 
were protected from hepatic decompensation. In patients with 
CSPH, an HVPG decrease  ≥  10% was similarly protective 
(36  months, 2.5% vs. 40.5%; P  <  0.001) but was observed 
in a substantially higher proportion of patients (60% vs. 
24%; P  <  0.001). Importantly, the performance of noninva-
sive methods such as TE/VITRO for diagnosing an HVPG 
reduction  ≥  10% was inadequate for clinical use (area under 
the receiver operating characteristic curve [AUROC],   <  0.8), 
emphasizing the need for HVPG measurements. However, 
TE/VITRO were able to rule in or rule out FU CSPH 
(AUROC, 0.86-0.92) in most patients, especially if assessed 
in a sequential manner.
CoNClUSIoNS: Reassessment of HVPG after SVR im-
proved prognostication in patients with pretreatment CSPH. 
An “immediate” HVPG decrease  ≥  10% was observed in the 
majority of these patients and was associated with a clinical 
benefit, as it prevented hepatic decompensation. These results 
support the use of HVPG as a surrogate endpoint for inter-
ventions that lower portal pressure by decreasing intrahepatic 
resistance. (Hepatology 2020;71:1023-1036).
Interferon (IFN)-free therapies have revolution-ized the treatment of patients with chronic hepa-titis C (CHC). Even in previous difficult-to-cure 
patient populations, such as patients with human 
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immunodeficiency virus coinfection(1,2) or compen-
sated advanced chronic liver disease (cACLD) and 
PH,(3,4) rates of sustained virologic response (SVR) 
increased to nearly 100%. Accordingly, the focus of 
attention has shifted to the regression of liver disease 
and risk stratification concepts for personalized follow- 
up (FU) of patients who had advanced chronic liver 
disease (ACLD) before treatment and achieved 
SVR.(5-7)
Four studies have investigated the impact of 
viral suppression by SVR to IFN-free treat-
ments on the evolution of PH,(8-11) as assessed 
by hepatic venous pressure gradient (HVPG). 
Although patients with pretreatment subclinical 
PH (i.e., HVPG 6-9  mm  Hg) did not progress to 
clinically significant portal hypertension (CSPH; 
HVPG ≥ 10 mm Hg(12-14)), less than one fourth of 
patients who had CSPH before treatment resolved 
CSPH.(8,10,11) Accordingly, the vast majority of 
patients remained at risk for hepatic decompensa-
tion despite the cure of hepatitis C virus (HCV) 
infection. However, nearly two thirds of patients 
with CSPH before antiviral therapy had an HVPG 
decrease  ≥  10% after achieving SVR to IFN-free 
regimens,(8,10) which denotes a clinically meaning-
ful decrease according to the Baveno VI chapter on 
the impact of etiological therapy.(13) This recom-
mendation is primarily based on studies evaluating 
the HVPG response to nonselective beta-blockers 
(NSBB).(15) However, there is also limited evidence 
from patients with HVPG ≥ 12 mm Hg due to alco-
holic liver disease (ALD) who were advised to abstain 
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from alcohol (HVPG decrease cutoff  ≥  15%),(16) or 
patients with compensated cirrhosis due to nonal-
coholic steatohepatitis (NASH) treated with simtu-
zumab or placebo (HVPG decrease cutoff ≥ 20%).(17) 
Besides variceal (re-)bleeding, HVPG response to 
conventional NSBB  ±  vasoactive drugs has been 
shown to decrease the risks of occurrence/worsening 
of ascites and its complications.(15) In addition, some 
studies even reported (trends toward) a decrease in 
hepatic encephalopathy (HE), a decompensating 
event that is less closely linked to PH.(15) However, 
conventional NSBB have completely different modes 
of action, as compared with etiological therapies or 
other treatments that primarily act by decreasing 
intrahepatic resistance.(18,19) HVPG is currently not 
accepted as a surrogate endpoint for the accelerated 
approval of medical therapies for PH by regulatory 
authorities, because there is limited evidence sup-
porting its use as a surrogate endpoint for other 
treatments than NSBB.(20) This is particularly prob-
lematic in patients with cACLD, in whom the inci-
dence of hepatic decompensation is comparatively 
low, resulting in tremendously larger trials and lon-
ger study periods, if clinical endpoints (e.g., hepatic 
decompensation) are assessed. Because resources are 
limited, only a minority of the emerging treatment 
approaches are tested in phase 3 clinical trials assess-
ing direct endpoints, which greatly inhibits scientific 
progress in the field of PH.(21)
Thus, we aimed to assess the impact of pretreat-
ment HVPG, changes in HVPG, and posttreatment 
values on the development of hepatic decompensation 
in patients with PH who achieved SVR to IFN-free 
therapy. Moreover, we investigated the use of transient 
elastography (TE) and von Willebrand factor (VWF) 
for monitoring the evolution of PH and the impact of 
HCV cure on markers of bacterial translocation and 
inflammation.(22)
Patients and Methods
StUDy DeSIgN aND popUlatIoN
Ninety patients with PH (HVPG ≥ 6 mm Hg(12-14)) 
who underwent HVPG and TE before (baseline 
[BL], October 2013 to April 2018) and after IFN-
free therapy at the Medical University of Vienna 
were prospectively characterized and followed for 
the development of clinical events after the end of 
treatment. An explorative analysis on changes in 
markers of bacterial translocation and inflamma-
tion (lipopolysaccharide-binding protein [LBP] and 
interleukin 6 [IL-6]) was performed in a subgroup 
of 73 patients.
Of note, a considerable proportion of our study 
cohort has been included in a previous study inves-
tigating the impact of SVR to IFN-free therapies 
on HVPG (and TE)(8); however, this previous study 
did not evaluate the association between hemody-
namic changes and clinical outcomes (i.e., the pri-
mary objective of the present study) or the impact 
of HCV cure on markers of bacterial translocation 
and inflammation.
ClINICal aND laBoRatoRy 
paRaMeteRS
VWF/platelet count (PLT) ratio (VITRO) was 
calculated by dividing VWF antigen levels (%) over 
PLT (G × L−1), as previously described.(23,24)
See Supporting Information for further information.
HCV tHeRapy
All patients were treated with IFN-free therapies. 
The choice of the regimen was at the physicians’ dis-
cretion and depended on the availability of early-access 
programs, reimbursement policies, and national(25,26) 
and international(27-29) clinical practice guidelines at 
the time of treatment initiation. Treatment durations 
ranged from 8 to 24 weeks.
HVpg aND lIVeR StIFFNeSS 
MeaSUReMeNt
HVPG measurements were performed by the 
Vienna Hepatic Hemodynamic Lab at the Medical 
University of Vienna in accordance with a standard-
ized operating procedure(30) and in the absence of 
NSBB and nitrates. In patients on NSBB, treatment 
was paused 5  days before HVPG measurements. 
Liver stiffness was measured using TE (FibroScan; 
Echosens, Paris, France).
In patients with CSPH (HVPG ≥ 10 mm Hg(12-14)), 
a clinically meaningful change in HVPG was defined 
by a decrease of ≥10%, as recommended by the Baveno 
VI consensus for etiologic therapies.(13) Subclinical 
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and pronounced PH were defined by an HVPG of 
6-9 mm Hg and ≥16 mm Hg, respectively.(12-14)
ClINICal eVeNtS
In patients with cACLD, hepatic decompensation 
was defined by variceal bleeding, incident ascites, or 
incident HE, whereas in patients with decompensated 
ACLD, further hepatic decompensation was defined 
by variceal (re-)bleeding, requirement of paracentesis, 
admission for grade 3/4 HE, or development of grade 
3/4 HE during admission.
Although new onset of jaundice is commonly referred 
to as a decompensating event in natural history stud-
ies,(31) we did not incorporate jaundice in the definition 
of hepatic decompensation, because this term is poorly 
defined.(32) This is in line with previous studies inves-




This study was conducted in accordance with 
the Declaration of Helsinki and approved by the 
local ethics committee of the Medical University 




The majority of patients were male (73%), with a 
mean age of 54.5  ±  1  years (Supporting Table S1). 
Overall, 22% of patients had a history of hepatic 
decompensation and 28% were Child-Turcotte-Pugh 
(CTP) score stage B, whereas no CTP score stage C 
patients were included. The median BL Model for 
End-Stage Liver Disease (MELD) score was 9 (3) 
points. All patients with varices and/or previous variceal 
bleeding (n = 34) were on NSBB treatment, except for 
4 patients in primary prophylaxis who were intoler-
ant to NSBB. Moreover, 8 additional patients received 
carvedilol for arterial hypertension. Accordingly, 
38 (42%) patients were receiving NSBB treatment. 
Median BL HVPG, which was assessed 1.71 (10.3) 
months before treatment initiation, was 14 (8) mm Hg. 
Twenty-three (26%) patients had subclinical PH (i.e., 
HVPG 5-9 mm Hg; median HVPG, 8 [3] mm Hg) at 
BL, whereas HVPG values of 10-15 mm Hg (median 
HVPG, 12 [4] mm  Hg) and ≥16  mm  Hg (median 
HVPG, 19 [4] mm  Hg) were observed in 29 (32%) 
and 38 (42%) patients, respectively. Accordingly, the 
prevalence of CSPH at BL was 74% (67/90).
Baseline characteristics of the subgroup of patients 
with pretreatment CSPH are shown in Table 1.
BaSelINe CHaRaCteRIStICS 
aCCoRDINg to tHe SeVeRIty 
oF pH
See Supporting Information.
CHaNge IN HepatIC VeNoUS 
pReSSURe gRaDIeNt aFteR 
tReatMeNt
The FU HVPG measurement was performed 8.79 
(6.67) months after the treatment initiation, which was 
4.15 (6.58) months after the end of IFN-free therapy.
Absolute and relative changes in HVPG in this 
series of 90 patients are depicted in Supporting Fig. S1  
and were consistent with our previous report on 
60 patients, who were also included in this study.(8) 
No patient with subclinical PH at BL progressed to 
CSPH (i.e., FU HVPG ≥ 10 mm Hg); however, 57% 
(13/23) of these patients 38/90 resolved PH (i.e., FU 
HVPG ≤ 5 mm Hg). Among patients with CSPH at BL, 
6% (4/67) of patients had an FU HVPG of ≤ 5 mm Hg, 
18% (12/67) of patients regressed to subclinical PH (i.e., 
HVPG  ≥  5-9  mm  Hg), and CSPH persisted in 76% 
(51/67). Of note, the proportion of patients with pro-
found PH (i.e., HVPG ≥ 16 mm Hg) decreased from 
57% (38/67) at BL to 33% (22/67) at FU.
Importantly, in patients with CSPH at BL, an HVPG 
decrease  ≥  10% was substantially more common (60% 
[40/67]) than a regression to HVPG values ≤ 9 mm Hg 
after antiviral therapy (24% [16/67]; P < 0.001).
SeVeRIty oF pH aND ClINICal 
eVeNtS
During a median follow-up of 35.3 (21.8) months, 
11 patients developed hepatic decompensation (n = 7 
first hepatic decompensation; n  =  4 further hepatic 
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taBle 1. Comparison of Bl Characteristics, Changes During antiviral therapy, and Characteristics at FU HVpg Measurement 
Between patients With CSpH at Bl Who Had or Did Not Have an HVpg Decrease ≥ 10%
Patient Characteristics All, n = 67 HVPG Decrease ≥ 10%, n = 40 No HVPG Decrease ≥ 10%, n = 27 P Value
Age, years 54.5 ± 1.18 56.1 ± 1.4 52.2 ± 2 0.101
Sex
Male 45 (67%) 25 (63%) 20 (74%) 0.428
Female 22 (33%) 15 (38%) 7 (26%)
BL BMI, kg × m−2 25.8 ± 0.6 25.8 ± 0.7 25.8 ± 1 0.966
≥25 kg × m−2 35 (52%) 20 (50%) 15 (56%) 0.655
≥30 kg × m−2 12 (18%) 7 (18%) 5 (19%) 1
Δ BMI, kg × m−2 0.211 (2.366) 0.106 (2.236) 0.316 (2.564) 0.691
FU BMI, kg × m−2 26 ± 0.6 26 ± 0.75 26 ± 0.91 0.976
≥25 kg × m−2 38 (57%) 23 (58%) 15 (56%) 0.875
≥30 kg × m−2 11 (16%) 6 (15%) 5 (19%) 0.745
Alcohol consumption
Abstinent 57 (85%) 34 (85%) 23 (85%) 0.517
Nonabstinent but below threshold* 5 (7%) 4 (10%) 1 (4%)
Above threshold* 5 (7%) 2 (5%) 3 (11%)
HCV genotype
1 45 (67%) 25 (63%) 20 (74%)
3 15 (22%) 11 (28%) 4 (27%) 0.545
4 7 (10%) 4 (10%) 3 (11%)
History of hepatic decompensation 13 (19%) 7 (18%) 6 (22%) 0.632
BL CTP score, points 6 (2) 6 (2) 7 (2) 0.075
Stage A 43 (64%) 30 (75%) 13 (48%) 0.037
Stage B 24 (36%) 10 (25%) 14 (52%)
Δ CTP score, points 0 (0) 0 (0) 0 (0) 0.577
FU CTP score, points 6 (2) 6 (1) 6 (3) 0.066
BL MELD score, points 9 (3) 9 (3) 10 (4) 0.009
Δ MELD score, points 0 (2) 0 (1) −1 (2) 0.521
FU MELD score, points 9 (2) 8 (3) 10 (4) 0.027
Varices 33 (49%) 17 (43%) 16 (59%) 0.178
Small 17 (52%) 10 (59%) 7 (44%) 0.387
Large 16 (48%) 7 (41%) 9 (56%)
NSBB treatment 35 (52%) 19 (48%) 16 (59%) 0.345
BL HVPG, mm Hg 16.2 ±0.5 15.8 ±0.6 16.7 ±0.9 0.395
≥16 mm Hg 38 (57%) 21 (53%) 17 (63%) 0.397
Absolute Δ HVPG, mm Hg −2.64 ± 0.46 −5.1 ± 0.34 0.93 ± 0.49 <0.001
Relative Δ HVPG, % −17.8 ± 2.9 −33 ± 2.3 4.56 ± 2.61 <0.001
FU HVPG, mm Hg 12 (7) 10.5 (5) 17 (11) <0.001
≤5 mm Hg 4 (6%) 4 (10%) 0 (0%) <0.001
6-9 mm Hg 12 (18%) 12 (30%) 0 (0%)
10-15 mm Hg 29 (43%) 19 (48%) 10 (37%)
≥16 mm Hg 22 (33%) 5 (13%) 17 (63%)
BL liver stiffness, kPa† 27.7 (25.4) 27 (19.7) 29.1 (24.1) 0.269
Absolute Δ liver stiffness, kPa† −4.6 (11.9) −6.8 (11) −3.6 (19.7) 0.004
Relative Δ liver stiffness, %† −18.1 (43.1) −31.9 (35.9) −8.22 (52.8) <0.001
FU liver stiffness, kPa† 23 (26) 19.1 (13.5) 32.4 (27) 0.002
BL PLT, G × L−1 83 (49) 100.5 (43) 68 (49) 0.004
Absolute Δ PLT, G × L−1 7.16 ± 2.95 8.73 ± 3.99 4.85 ± 4.36 0.523
Relative Δ PLT, G × L−1 8.11 (27.89) 8.6 (24.79) 3.03 (26.28) 0.51
FU PLT, G × L−1 89 (64) 101 (62) 77 (59) 0.015
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decompensation): n = 5 ascites, n = 5 HE, and n = 1 
variceal bleeding. Three patients underwent liver 
transplantation. The death of 1 patient with further 
hepatic decompensation was considered liver related, 
whereas 1 compensated patient died of a non-liver- 
related (cardiac) cause.
Although there was only a trend toward an 
increased risk of posttreatment hepatic decompensa-
tion with increasing BL HVPG (per mm Hg, hazard 
ratio [HR], 1.13; 95% confidence interval [CI], 0.94-
1.28; P = 0.069), FU HVPG showed a strong associ-
ation with hepatic decompensation (per mm Hg; HR, 
1.18; 95% CI, 1.08-1.28; P  <  0.001). Accordingly, 
although BL HVPG stratified patients into subgroups 
with different risks of hepatic decompensation after 
treatment (log-rank: P = 0.04; Fig. 1), its discrimina-
tory ability seemed to improve if HVPG was assessed 
during FU: Whereas none of the patients with FU 
HVPG ≤ 9 mm Hg (0/39) had hepatic decompensa-
tion, the Kaplan-Meier estimates for hepatic decom-
pensation at 36 months in patients with FU HVPG 
values of 10-15 mm Hg and ≥16 mm Hg were 11.1% 
and 40.1%, respectively.
CoRRelatIoN BetWeeN tHe 
CHaNge IN HepatIC VeNoUS 
pReSSURe gRaDIeNt aFteR 
tReatMeNt aND ClINICal 
eVeNtS
In the population at risk for hepatic decompen-
sation (i.e., patients with CSPH at BL), FU HVPG 
(area under the receiver operating characteristic curve 
[AUROC], 0.819; 95% CI, 0.687-0.951; P = 0.001) as 
well as the absolute (AUROC, 0.872; 95% CI, 0.74-
1; P < 0.001) and relative (AUROC, 0.877; 95% CI, 
0.749-1; P  <  0.001) changes in HVPG were associ-
ated with hepatic decompensation. In contrast, BL 
HVPG was not predictive (AUROC, 0.657; 95% CI, 
0.468-0.951; P = 0.101).
Although the highest Youden’s index was observed 
at a relative HVPG decrease of 5% (sensitivity, 90.9%/
specificity, 80.4%), we used the similarly sensitive but 
slightly less specific 10% cutoff (sensitivity, 90.9%/
specificity, 69.6%) for further analyses, as recom-
mended by the Baveno VI chapter on the impact of 
etiological treatment.(13)
Patients with CSPH at BL who achieved an 
HVPG decrease ≥ 10% had a substantially lower risk 
of hepatic decompensation after treatment (2.5% vs. 
40.5% at 36  months; P  <  0.001; Fig. 2). The results 
remained basically unchanged, if only events occurring 
after the FU HVPG-measurement were considered 
(2.6% vs. 30.7% at 36 months; P = 0.003). When strat-
ifying patients according to the presence or absence 
of previous hepatic decompensation, patients with 
compensated CSPH at BL (n = 54) were completely 
protected from hepatic decompensation, if HVPG 
decreased by  ≥  10% (0% vs. 36.4% at 36  months; 
P  <  0.001). In the limited number of patients with 
decompensated CSPH included in our study (n = 13), 
the difference in the risk of further hepatic decom-
pensation (14.3% vs. 55.6% at 36 months; P  =  0.22) 
did not attain statistical significance.
Importantly, achieving an HVPG decrease  ≥  10% 
was associated with a substantially decreased risk of 
hepatic decompensation (adjusted HR, 0.102; 95% 
CI, 0.012-0.863; P  =  0.036), even when accounting 
Patient Characteristics All, n = 67 HVPG Decrease ≥ 10%, n = 40 No HVPG Decrease ≥ 10%, n = 27 P Value
BL VWF, %‡ 293 (151) 283 ± 15.7 311 ± 18 0.267
Absolute Δ VWF, %‡ −58 (90) −83.3 ± 10 −26.6 ± 8.8 <0.001
Relative Δ VWF, %‡ −19.1 (26.4) −30.1 (23.5) −9.7 (19.9) <0.001
FU VWF, %‡ 202 (141) 179 (88) 275 (198) 0.003
BL VITRO, %‡ 3.38 (3.42) 2.98 (2.41) 4.64 (3.56) 0.014
Absolute Δ VITRO‡ −0.791 (1.176) −0.979 (1.442) −0.382 (1.532) 0.002
Relative Δ VITRO, %‡ −25.5 (38.6) −34.1 (28.9) −11.2 (43.7) 0.013
FU VITRO, %‡ 2.4 (2.64) 1.96 (1.96) 3.31 (4.56) 0.002
*>30 g/day and >20 g/day for males and females, respectively.(48)
†Information available in 64 patients.
‡Information available in 65 patients.
Abbreviation: BMI, body mass index.
taBle 1. Continued
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for history of hepatic decompensation as well as treat-
ment-induced changes in CTP and MELD score, or 
their posttreatment values (Table 2).
CoMpaRISoN WItH otHeR 
poteNtIal DeFINItIoNS oF 
HVpg ReSpoNSe
Using more restrictive definitions of HVPG 
response, such as an HVPG decrease  ≥  20%, HVPG 
decrease  ≥  20% or to ≤9  mm  Hg, or an 
HVPG decrease ≥ 20% or to ≤ 12 mm Hg (in the sub-
group of patients with BL HVPG > 12 mm Hg), did 
not increase the sensitivity for hepatic decompensation 
during FU, because 1 decompensated patient with 
HVPG response developed further hepatic decompen-
sation, regardless of the definition used (Supporting 
Table S2). However, a lower proportion of patients 
(49%-51%) achieved HVPG response according to 
these definitions, and thus, additional patients without 
hepatic decompensation were assigned to the HVPG 
nonresponse group. Accordingly, the probability of 
hepatic decompensation in patients with HVPG non-
response tended to decrease, suggesting an inferior dis-
criminatory ability of these more restrictive definitions 
of HVPG response.
pH aND DE NOVO 
HepatoCellUlaR CaRCINoMa
Six patients were diagnosed with de novo hepato-
cellular carcinoma (HCC), who all had CSPH at BL. 
However, HCC seemed to develop independently of 
the evolution of PH during treatment: Two patients 
who developed FU HCC showed an HVPG decrease 
to  ≤  9  mm  Hg at FU. Moreover, 83% (5/6) had an 
HVPG decrease ≥ 10%.
FaCtoRS aSSoCIateD WItH 
aN HVpg DeCReaSe ≥ 10% IN 
patIeNtS WItH pRetReatMeNt 
CSpH
Please see Table 1 and the Supporting Information.
NoNINVaSIVe DIagNoSIS 
oF CSpH at FU aND HVpg 
DeCReaSe ≥ 10%
In the overall study population, liver stiffness 
(AUROC, 0.92; 95% CI, 0.863-0.978; P  <  0.001), 
platelet count (AUROC, 0.816; i.e., 1  minus 0.184, 
due to indirect association; 95% CI, 0.724-0.908; 
P < 0.001), VWF (AUROC, 0.807; 95% CI, 0.714-
0.9; P < 0.001), and VITRO (AUROC, 0.877; 95% 
CI, 0.802-0.952; P < 0.001) showed a high diagnos-
tic accuracy for CSPH at FU (Supporting Table S3; 
Fig. 3).
The diagnostic indices of the previously defined 
FU liver stiffness cutoffs for ruling out (12.4  kPa; 
sensitivity, 97.9%) and ruling in FU CSPH (25.3 kPa; 
specificity, 94.4%)(8) remained unchanged despite add-
ing additional patients, with 39.3% (33/84) of patients 
being unclassifiable. The false-negative patient had 
an FU liver stiffness of 11.8 kPa and an FU HVPG 
value of 17  mm  Hg and did not achieve an HVPG 
response ≥ 10%; however, this patient did not develop 
hepatic decompensation.
FIg. 1. Cumulative incidence of hepatic decompensation after treatment according to (A) BL and (B) FU HVPG strata.
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The newly defined FU VITRO cutoffs for rul-
ing out and ruling in FU CSPH were 0.95 (sensi-
tivity, 95.8%) and 3.3 (specificity, 94.4%), with 53.6% 
(45/84) of patients in the diagnostic gray zone. The 
false-negative patient had an FU VITRO 0.92, an 
FU liver stiffness of 17.1  kPa, and an FU HVPG 
value of 17  mm  Hg and did not achieve an HVPG 
response ≥ 10%; however, this patient did not develop 
hepatic decompensation.
Using these tests sequentially (i.e., assessing FU 
VITRO in patients who were unclassifiable based 
on FU liver stiffness and vice versa) statistically sig-
nificantly decreased the proportion of patients in 
the diagnostic gray zone to 25% (21/84; P  =  0.047 
FIg. 2. Cumulative incidence of hepatic decompensation after treatment according to HVPG decrease ≥ 10% from BL to FU. (A) All 
patients with CSPH at BL, (B) all patients with CSPH at BL, only considering events that occurred after the FU HVPG measurement, 
and subgroups of patients with (C) compensated CSPH and (D) decompensated CSPH at BL.
taBle 2. Univariate and Multivariate Cox Regression analyses on Determinants of Hepatic Decompensation after 
treatment
Parameter
Univariate Analysis, n = 67 Multivariate Analysis, n = 67
HR 95% CI P Value aHR 95% CI P Value
History of hepatic decompensation 2.5 0.732-8.56 0.166 — — —
Change in CTP score, per point 1.55 0.84-2.87 0.179 — — —
FU CTP score, per point 2.11 1.45-3.06 < 0.001 1.484 1.01-2.17 0.043
Change in MELD score, per point 1.26 0.9-1.76 0.176 — — —
FU MELD score, per point 1.25 1.13-1.38 0.001 1.15 1.01-1.32 0.042
HVPG decrease ≥ 10% 0.056 0.007-0.483 0.006 0.102 0.012-0.863 0.036
Abbreviation: aHR, adjusted hazard ratio.
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and P  < 0.001 compared with FU liver stiffness and 
VITRO alone, respectively), while maintaining a high 
sensitivity (liver stiffness first, 93.8%; VITRO first, 
93.8%) and specificity (liver stiffness first, 87.1%; 
VITRO first, 90.3%) for ruling out and ruling in FU 
CSPH, respectively.
Interestingly, the diagnostic performance of liver 
stiffness tended to worsen if the regression of CSPH 
was assessed, i.e., when the analysis was restricted to 
patients with CSPH at BL (AUROC, 0.86; 95% CI, 
0.751-0.969; P < 0.001). In contrast, the AUROC of 
PLT and VWF numerically increased in this subgroup 
of patients, with VITRO showing the highest diag-
nostic accuracy (AUROC, 0.876; 95% CI, 0.749-1; 
P < 0.001) of all assessed parameters.
Although liver stiffness, platelet count, VWF, and 
VITRO, as well as their relative/absolute changes 
during treatment, showed statistically significant asso-
ciations with HVPG decrease  ≥  10%, all AUROC 
values were below 0.8.
FIg. 3. Performance of noninvasive markers for diagnosing CSPH at FU. Bold lines indicate parameters statistically significantly 
associated with the condition. (A) All patients (AUROC: *0.92; **0.816, i.e., 1 minus 0.184, due to indirect association; ***0.807; 
****0.877). (B) Subgroup of patients with CSPH at BL (AUROC: *0.86; **0.836, i.e., 1 minus 0.164, due to indirect association; ***0.822; 
****0.876).
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eVolUtIoN oF HVpg aND 
HepatIC DeCoMpeNSatIoN 
DURINg loNg-teRM FU
Thirteen (19%) out of 67 patients with CSPH at 
BL underwent an additional HVPG measurement 
(“last”) after the first assessment of FU HVPG. 
These HVPG measurements were performed 
31.2  ±  3.4  months after treatment initiation, which 
was 26.8  ±  3.36  months after the end of IFN-free 
therapy and 20.1  ±  2.8  months after the first post-
treatment HVPG measurement.
In these selected patients, HVPG decreased from 
15.2 ± 1.7 to 11.8 ± 1.8 mm Hg, which corresponds 
to an absolute change of −3.38  ±  0.68  mm  Hg 
(P  <  0.001) and a relative change of −24.4  ±  4.1% 
(Supporting Fig. S2). The proportion of patients who 
resolved CSPH increased from 15% (2/13) at the 
second (“FU”) assessment to 46% (6/13) at the last 
HVPG measurement. Seven (54%) out of 13 patients 
had achieved an HVPG decrease  ≥  10% at the sec-
ond (“FU”) HVPG assessment, which was main-
tained in all patients. Moreover, 4 additional patients 
achieved an HVPG decrease ≥ 10% at the last mea-
surement, resulting in an overall rate of long-term 
HVPG decrease ≥ 10% of 85% (11/13) in this series 
of patients.
Interestingly, we observed a close correlation 
between hemodynamic changes and the patients’ clin-
ical course: Whereas all (11/11) patients who main-
tained/achieved an HVPG decrease  ≥  10% at last 
HVPG measurement had an uneventful posttreat-
ment FU period (including 5 patients with a history 
of hepatic decompensation), both patients without a 
decrease ≥ 10% at last HVPG had hepatic decompen-
sation (Fig. 4).
eXploRatoRy aNalySIS oN 





The approval of highly effective IFN-free ther-
apies has ushered in a new era in the treatment of 
CHC.(2,4) Because even in patients with PH, SVR is 
almost universal, CHC is seen as an excellent model 
for the study of liver disease regression after the cure 
of the primary etiologic factor.
Although viral suppression in chronic hepatitis B 
may have comparable effects,(35) its effect on HVPG 
has only been studied in a small series of patients and 
was not correlated with direct endpoints. Moreover, 
despite the high prevalence of ALD, information 
on the impact of alcohol abstinence on HVPG and 
its predictive value for clinical events is limited.(16) 
Finally, the prognostic impact of HVPG decreases due 
to pharmacological therapies for NASH is currently 
being investigated. The results of a recent randomized 
controlled trial on simtuzumab, a monoclonal antibody 
against lysyl oxidase-like 2, in patients with compen-
sated cirrhosis suggest that an HVPG decrease ≥ 20% 
is associated with a lower risk of hepatic decompen-
sation.(17) However, simtuzumab has been found to be 
ineffective in this setting, and one third of patients 
included in this analysis have been assigned to the 
placebo group.(36) Thus, this study confirms the prog-
nostic value of HVPG and its changes over time in 
compensated NASH cirrhosis rather than provid-
ing strong evidence for the use of HVPG response 
as a surrogate outcome for the clinical effectiveness 
of an etiological treatment.(17) Accordingly, insights 
from patients with CHC are of great importance 
for advancing the understanding of the association 
between changes in HVPG due to therapies target-
ing intrahepatic resistance (i.e., etiological treatments) 
and clinical outcomes. Evidence from such studies is 
essential for promoting HVPG as a surrogate end-
point accepted by regulatory authorities.
FIg. 4. Evolution of HVPG in 13 patients who underwent 
an additional (“last”) HVPG measurement after the first FU 
measurement and correlation with hepatic decompensation after 
treatment.
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In a previous study investigating hemodynamic 
changes during antiviral therapy with pegylated inter-
feron and ribavirin, pretreatment HVPG/CSPH was 
predictive of hepatic decompensation during fol-
low-up.(37) However, because of the low efficacy of 
this regimen in patients with cirrhosis, only a minority 
achieved SVR, and thus, the prognostic impact of 
changes in HVPG and posttreatment values was not 
assessed. Although pretreatment HVPG strata were 
predictive of clinical events in our study, the discrim-
inatory ability of these HVPG strata improved sub-
stantially when posttreatment HVPG values were 
considered. This may be explained by patients with 
pretreatment CSPH being reclassified as having no 
or only subclinical PH (i.e., HVPG  ≤  9  mm  Hg) 
after treatment, which was fully protective of hepatic 
decompensation. In addition, the proportion of 
patients with profound PH (HVPG  ≥  16  mm  Hg, 
i.e., patients at high risk for hepatic decompensation) 
decreased after treatment, which may have enriched 
this subgroup with patients who have already passed 
a potential point of no return in the natural history 
of liver disease, resulting in a particularly bad progno-
sis. Accordingly, posttreatment but not pretreatment 
HVPG was predictive of hepatic decompensation in 
AUROC analysis if only patients at risk (i.e., patients 
with pretreatment CSPH) were considered. This is 
in line with the recent observation that a dynamic 
model based on serial HVPG measurements is closely 
linked with the risk of hepatic decompensation 
and/or death.(38)
However, the concept of using HVPG cutoffs for 
risk stratification has an important limitation, which 
has also been observed in studies assessing the HVPG 
response to NSBB.(15) Although a decrease below a 
certain cutoff (i.e., HVPG  ≤  12  mm  Hg) was pro-
tective and thus highly sensitive for (recurrent) var-
iceal bleeding, such a decrease was only achieved by 
a small proportion of patients. Therefore, this cutoff 
was combined with the more commonly obtained 
HVPG reduction by  ≥  20% to increase the specific-
ity of HVPG response.(15) In order to further increase 
the positive predictive value (PPV) of this definition 
in patients at a lower risk of variceal bleeding, the 
Baveno VI faculty recently adopted the more specific 
10% cutoff for primary prophylaxis.(13) Interestingly, 
the Youden’s index-derived optimal cutoff would 
have been ≥5% in our study; however, consider-
ing the imprecision of the measurement, using this 
cutoff may have substantially limited the reproduc-
ibility of HVPG response assessment in patients with 
HVPG < 20 mm Hg. Accordingly, we used the slightly 
less specific 10% cutoff, which is also recommended 
by the Baveno VI chapter on the impact of etiological 
treatment.(13) On the one hand, it cannot be ruled out 
that treatments targeting intrahepatic resistance (e.g., 
statins) have beneficial effects despite achieving less 
pronounced but consistent reductions in HVPG.(20) 
Especially in patients undergoing etiological therapy, 
even small changes may denote a trend in the “right” 
direction (i.e., disease regression). However, on the 
other hand, the required HVPG reduction could also 
be higher,(39) because of the absence of the nonhe-
modynamic effects of NSBB.(18,19) In our study, more 
restrictive definitions of HVPG response (e.g., HVPG 
decrease ≥ 20%) seemed to worsen its discriminatory 
ability, which argues against the latter hypothesis.
In patients with pretreatment CSPH, an HVPG 
reduction  ≥  10% translated into a clinical benefit, 
especially in patients with cACLD who were com-
pletely protected from hepatic decompensation. In 
contrast, the trend toward a lower risk of further 
hepatic decompensation in patients with an HVPG 
decrease ≥ 10% did not attain statistical significance, 
which may be explained by the low number (n = 13) 
of patients with decompensated CSPH included in 
our study. Data obtained in a series of 13 patients 
with posttreatment CSPH undergoing a third HVPG 
measurement further strengthened the link between 
relative changes in HVPG and hepatic decompen-
sation. Importantly, the use of relative changes in 
HVPG, rather than posttreatment HVPG, substan-
tially increased the proportion of patients correctly 
identified as being at low risk (i.e., specificity/PPV of 
HVPG response). This is in line with the findings of 
the abovementioned studies, which defined HVPG 
response to NSBB treatment.
In line with previous reports,(8,10) patients with 
more advanced liver disease were less likely to achieve 
HVPG response, possibly because of the perpetua-
tion of mechanisms promoting PH in some of these 
patients. Although pretreatment values of HVPG and 
most noninvasive markers of PH were comparable 
between patients with an HVPG reduction  ≥  10%, 
or without, we observed profound differences in the 
absolute and relative changes, as well as posttreat-
ment values of liver stiffness, VWF, and VITRO 
score, indicating that these markers of PH may have 
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utility for the noninvasive monitoring of the evolu-
tion of PH after SVR.
Although HVPG measurement is generally safe 
and well tolerated,(40) its clinical use is limited by its 
invasiveness, and its availability is mostly restricted 
to academic centers. Accordingly, the development/
validation of noninvasive methods is essential for 
promoting personalized medicine in patients with 
ACLD who achieved SVR. Posttreatment liver 
stiffness and VITRO showed an excellent diagnos-
tic performance for FU CSPH. Nevertheless, when 
restricting the analysis to patients with pretreatment 
CSPH in order to evaluate the regression of CSPH, 
the AUROC of TE numerically decreased, whereas 
the AUROC of VITRO increased. This might be a 
consequence of liver stiffness being less strongly cor-
related with HVPG at values  ≥  10-12  mm  Hg in 
patients without NSBB treatment,(41) and VWF may 
show a better correlation with HVPG in this patient 
population.(22,42)
We confirmed the diagnostic value of our pre-
viously defined liver stiffness cutoffs (sensitivity/ 
specificity of about 95%) for ruling in (25.3 kPa) and 
ruling out (12.4 kPa) posttreatment CSPH; however, 
a high proportion of patients were unclassifiable. 
Applying VITRO cutoffs chosen to obtain similar 
sensitivity and specificity (ruling out, 0.95/ruling in, 
3.3), the proportion of patients within the diagnos-
tic gray zone was even higher. However, perform-
ing these tests in a sequential manner substantially 
reduced the proportion of unclassifiable patients and 
thus increased their potential value for clinical prac-
tice. In addition, Thabut and colleagues(43) recently 
validated the Baveno VI criteria for screening for 
high-risk varices in patients with SVR/viral suppres-
sion. Accordingly, there is an increasing number of 
noninvasive tools that may guide clinical decision 
making in this setting. Still, these noninvasive meth-
ods do not confer the same information as HVPG 
response, as they are incapable of monitoring the 
dynamics of PH with adequate accuracy. It would 
have been interesting to assess the diagnostic per-
formance of spleen stiffness in this setting, because 
changes in spleen stiffness have recently shown some 
promise as a noninvasive marker of HVPG response 
to carvedilol.(44) Future studies assessing clinical end-
points in larger cohorts should aim to refine the use 
of combinations and/or serial assessments of nonin-
vasive tests for risk stratification.
SVR to IFN-free therapy was associated with 
a decrease in LBP and tended to lower IL-6 levels. 
However, changes were highly heterogenous and 
independent of the evolution of PH. Interestingly, a 
similar pattern has been observed in a study investi-
gating the impact of NSBB treatment on measures of 
gastrointestinal permeability and LBP/IL-6 levels.(45) 
Although NSBB treatment lowered HVPG and 
decreased all of these parameters, the changes were 
not interrelated. This may suggest that PH and bac-
terial translocation as well as inflammation are not as 
closely linked as assumed by some authors. Moreover, 
a recent study demonstrated substantial interindi-
vidual variability in measures of inflammation (i.e., 
peaks of IL-6 that resolved spontaneously),(46) which 
may have interfered with the analysis of repeated 
assessments.
Of note, de novo HCC occurred only in patients 
with pretreatment CSPH, which is in line with the 
previous observations that patients with CSPH bear 
a 6-fold increased risk of HCC(47) as compared with 
patients with cirrhosis but without CSPH. However, 
incident HCC was not linked to the changes in PH, 
as it commonly occurred in patients who showed clear 
evidence of liver disease regression. This suggests that 
despite the amelioration of hepatic inflammation,(9) 
previously acquired genetic alterations and residual 
morphological changes/changes in the hepatic micro-
environment in patients with pretreatment CSPH 
may play a central role in hepatocarcinogenesis after 
SVR. Because death due to complications of PH was 
rare, we would like to highlight the importance of 
screening programs for the timely diagnosis of HCC 
in these patients, who otherwise mostly have a favor-
able prognosis.(5,7)
We must acknowledge several limitations of our 
study. Because of limited sample size, we combined 
patients with cACLD and decompensated ACLD for 
the main analyses. However, we were able to confirm 
the prognostic value of an HVPG decrease  ≥  10% 
in an analysis restricted to the important subgroup 
of patients with cACLD. Finally, we abstained from 
performing competing risk analyses,(31) as the inci-
dence of competing risks (i.e., liver transplantation/
death without previous hepatic decompensation) was 
very low. Furthermore, it cannot be assumed that the 
observations on long-term changes in HVPG are gen-
eralizable, as only a minority of patients underwent 
an additional (“last”) HVPG measurement, which 
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may have led to selection bias. However, the profound 
long-term changes in HVPG raise questions about 
the optimal time point for the assessment of posttreat-
ment HVPG. In our study, the time intervals between 
the end of treatment and posttreatment HVPG mea-
surements were not standardized, although they were 
within a reasonable range in all patients. The median 
time span was close to the time to SVR assessment 
(i.e., 12 weeks). A later assessment may have resulted 
in more pronounced decreases in HVPG, which may 
have increased the rate of an HVPG reduction ≥ 10% 
and thus may have restratified more patients to low-
er-risk HVPG strata. However, it would have also led 
to a higher number of episodes of hepatic decom-
pensation occurring before the posttreatment HVPG 
measurement.
In conclusion, reassessment of HVPG after the 
cure of hepatitis C improved prognostication. Patients 
with subclinical PH before/after IFN-free treatment 
are at negligible risk for hepatic decompensation, as 
we did not observe progression to CSPH. The cure 
of the primary etiologic factors induced an “immedi-
ate” HVPG decrease  ≥  10% in 60% of patients with 
pretreatment CSPH, which translated into a clinically 
meaningful benefit, as it prevented hepatic decom-
pensation. This finding provides important evidence 
for the use of HVPG as a surrogate endpoint for 
interventions that lower portal pressure by decreas-
ing intrahepatic resistance. Noninvasive methods such 
as TE and VITRO score cannot substitute HVPG 
measurement, as they are incapable of monitoring the 
dynamics of PH with adequate accuracy; however, 
they may be used for ruling in or ruling out posttreat-
ment CSPH.
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